Pesquisar
Harrow Inc
HROWAdicionar à lista de desejos
41.500USD
-1.180-2.76%
Fechamento 06/25, 16:00（ET）Cotações atrasadas em 15 min
1.55BValor de mercado
PerdaP/L TTM
Mais detalhes de Harrow Inc Empresa
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Informações de Harrow Inc
Código da empresaHROW
Nome da EmpresaHarrow Inc
Data de listagemFeb 08, 2013
CEOMullery (Frank)
Número de funcionários382
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 08
Endereço1A Burton Hills Blvd
CidadeNASHVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal37215
Telefone16157334731
Sitehttps://www.harrow.com/
Código da empresaHROW
Data de listagemFeb 08, 2013
CEOMullery (Frank)
Executivos da empresa Harrow Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Harrow Inc?
Os cinco principais acionistas de Harrow Inc são: Mr. Mark L. Baum, J.D.
Quantas instituições possuem ações da Harrow Inc (HROW)?
Em 2026Q1, 418 instituições possuíam ações da Harrow Inc, com valor de mercado aproximado de 24.67M, representando 66.17% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 347374.00.
